Kailera Therapeutics, Inc. (KLRA)
NASDAQ: KLRA · Real-Time Price · USD
20.68
-0.33 (-1.57%)
At close: Jul 10, 2026, 4:00 PM EDT
21.02
+0.34 (1.64%)
After-hours: Jul 10, 2026, 7:49 PM EDT

Kailera Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025
Period Ending
Dec '25
Selling, General & Admin
49.23
Research & Development
109.11
Total Operating Expenses
158.34
Operating Income
-158.34
Interest Income
11.05
Other Non-Operating Income (Expense)
-1.66
Total Non-Operating Income (Expense)
9.39
Pretax Income
-148.96
Net Income
-148.96
Net Income to Common
-148.96
Shares Outstanding (Basic)
0
Shares Outstanding (Diluted)
0
EPS (Basic)
-949.00
EPS (Diluted)
-949.00
Free Cash Flow
-122.3
Free Cash Flow Per Share
-778968.00
EBITDA
-158.03
EBIT
-158.34
SEC Filings: 10-K · 10-Q